View Older Stories View More Recent Stories

Nov 22, 2023 08:00AM Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Insomnia or Anxiety
Nov 20, 2023 08:00AM Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency (EMA)
Nov 6, 2023 08:00AM Anavex Life Sciences Appoints Senior VP of Regulatory Affairs
Oct 25, 2023 08:00AM Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX®3-71 to Prevent Cognitive Decline in Alzheimer’s Disease
Sep 14, 2023 07:30AM Anavex's (AVXL) Phase 2b/3 Trial of Blarcamesine Shows Robust Clinical Efficacy and Slows Neurodegeneration
Sep 14, 2023 07:30AM Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration
Sep 12, 2023 07:32AM Anavex Life Sciences (AVXL) Appoints Marwan N Sabbagh as Chair of Scientific Advisory Board
Sep 12, 2023 07:30AM Anavex Announces Appointment of Dr. Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board
Aug 8, 2023 07:30AM Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results
Aug 7, 2023 07:33AM Anavex Life Sciences (AVXL) Reports Publication of ANAVEX3-71 in Clinical Journal Confirming ANAVEX®3-71 Clinical Cardiovascular Safety
Aug 7, 2023 07:30AM Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming ANAVEX®3-71 Clinical Cardiovascular Safety
Aug 2, 2023 07:30AM Anavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023
Aug 1, 2023 07:30AM Anavex Life Sciences to Announce Fiscal 2023 Third Quarter Financial Results on Tuesday August 8, 2023
Jun 28, 2023 07:30AM Anavex Life Sciences (AVXL) Reports Study Showing Disease Modifying Effects of ANAVEX2-73 for Rett Syndrome
Jun 28, 2023 07:30AM Long-term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX®2-73 (blarcamesine) for Rett Syndrome
Jun 27, 2023 07:30AM Anavex Life Sciences and Partex Group Announce Strategic Partnership to Leverage AI for Drug Development and Healthcare Sales Marketing Building a Patient-Centric Digital Ecosystem
Jun 20, 2023 07:30AM Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Jun 15, 2023 07:31AM Anavex's (AVXL) blarcamesine Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome
Jun 15, 2023 07:30AM ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome
Jun 12, 2023 07:30AM Anavex Life Sciences Reports Publication in Medical Journal Signifying Continued Commitment for Improvement of the Rett Syndrome Caregiver Outcome Measure RSBQ
Jun 6, 2023 07:30AM Anavex Life Sciences Announces Completion of ANAVEX(®)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Jun 1, 2023 07:30AM Anavex Life Sciences (AVXL) Announces Issuance of New U.S. Intellectual Property Compositions Patent for ANAVEX®2-73
Jun 1, 2023 07:30AM ANAVEX Announces Issuance of New U.S. Intellectual Property Compositions Patent for ANAVEX®2-73 (blarcamesine)
May 9, 2023 07:30AM Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results
May 2, 2023 07:30AM Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Results on Tuesday, May 9, 2023
May 1, 2023 07:31AM Anavex Life Sciences (AVXL) Announces Issuance of New U.S. Patent Expanding ANAVEX®2-73 (blarcamesine) Intellectual Property Portfolio for the Treatment of Hypertension
May 1, 2023 07:30AM Anavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX®2-73 (blarcamesine) Intellectual Property Portfolio for the Treatment of Hypertension
Apr 25, 2023 07:30AM Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
Apr 10, 2023 07:00AM Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023
Mar 30, 2023 07:01AM Anavex Life (AVXL) Reports ANAVEX2-73 Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study
Mar 30, 2023 07:00AM ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson’s Disease Dementia
Mar 9, 2023 07:00AM Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as Vice President Head of Biostatistics
Feb 7, 2023 07:00AM Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results
Feb 2, 2023 07:00AM Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Jan 31, 2023 07:00AM Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on Tuesday February 7, 2023
Dec 14, 2022 07:00AM Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial
Dec 12, 2022 07:00AM Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 2, 2022 04:30PM Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022
Dec 2, 2022 07:12AM Anavex Life Sciences (AVXL) Phase 2b/3 of ANAVEX 2-73 in Early Alzheimer's Disease Met Primary and Key Secondary Endpoints
Dec 1, 2022 08:26PM ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early
Nov 28, 2022 07:00AM Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update
Nov 23, 2022 07:00AM Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022
Nov 8, 2022 07:00AM Anavex Life Sciences to Present at the Guggenheim 4th Annual Immunology and Neurology Conference 2022
Nov 7, 2022 07:04AM Anavex Life Sciences (AVXL) Granted FDA Orphan Drug Designation for ANAVEX2-73
Nov 7, 2022 07:00AM Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X Syndrome
Oct 17, 2022 07:05AM Anavex Life Sciences (AVXL) Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer’s Disease at the Upcoming CTAD Congress
Oct 17, 2022 07:00AM Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer’s Disease at the Upcoming Clinical Trials on Alzheimer’s Diseas
Sep 21, 2022 07:03AM Anavex Life Sciences (AVXL) Announces Issuance of U.S. Patent Covering ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders Therapy
Sep 21, 2022 07:00AM Anavex Life Sciences Announces Issuance of U.S. Patent Covering ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders Therapy
Aug 23, 2022 07:00AM Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer's Disease
View More Recent Stories View Older Stories